Literature DB >> 15285526

Diagnostic value of faecal calprotectin in paediatric gastroenterology clinical practice.

R Berni Canani1, L Rapacciuolo, M T Romano, L Tanturri de Horatio, G Terrin, F Manguso, P Cirillo, F Paparo, R Troncone.   

Abstract

BACKGROUND: Faecal calprotectin (FC) is a new marker of intestinal inflammation. Data on FC in paediatric gastroenterology clinical practice are still scarce. AIMS: To assess FC values in different paediatric gastrointestinal diseases comparing them with those obtained in healthy children. PATIENTS: Two hundred and eighty-one children (age range 13-216 months) consecutively referred for gastrointestinal symptoms. Seventy-six healthy controls (age range 13-209 months). The exclusion criteria in healthy children were the following: any known underlying chronic disease or a history of abdominal pain, diarrhoea, acute respiratory tract infection, intake of non-steroidal anti-inflammatory drugs, gastric acidity inhibitors, antibiotics, drugs influencing gut motility, and menstrual or nasal bleeding in the last 3 weeks.
METHODS: Stool samples stored, prepared and analyzed by an ELISA assay.
RESULTS: In healthy children the median FC value was 28.0 microg/g (15-57 interquartile range) with a 95th percentile value of 95.3 microg/g. An increase in FC concentration was observed in all diseases characterized by gastrointestinal mucosa inflammation, and the active inflammatory bowel disease patients showed the higher FC values. All children affected by functional bowel disorders or by non-inflammatory diseases showed normal values. We calculated an optimized FC cut off value of 102.9266 microg/g (revealed by the receiver operating characteristic curve) to distinguish patients with active organic/inflammatory disorders from healthy subjects and from patients with functional bowel disorders.
CONCLUSIONS: Calprotectin is a sensitive, but not disease specific, marker to easily detect inflammation throughout the whole gastrointestinal tract. It may help in identifying an organic disease characterized by intestinal mucosa inflammation and in the differential diagnosis of functional bowel disorders.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15285526     DOI: 10.1016/j.dld.2004.02.009

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  51 in total

Review 1.  Diagnostic accuracy of fecal lactoferrin for inflammatory bowel disease: a meta-analysis.

Authors:  Yan Wang; Fengyan Pei; Xingjuan Wang; Zhiyu Sun; Chengjin Hu; Hengli Dou
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

2.  Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome.

Authors:  T Kaiser; J Langhorst; H Wittkowski; K Becker; A W Friedrich; A Rueffer; G J Dobos; J Roth; D Foell
Journal:  Gut       Date:  2007-08-03       Impact factor: 23.059

Review 3.  Interactions of the innate and adaptive arms of the immune system in the pathogenesis of spondyloarthritis.

Authors:  M L Stoll
Journal:  Clin Exp Rheumatol       Date:  2011-04-19       Impact factor: 4.473

4.  Low dietary iron intake restrains the intestinal inflammatory response and pathology of enteric infection by food-borne bacterial pathogens.

Authors:  Guus A M Kortman; Michelle L M Mulder; Thijs J W Richters; Nanda K N Shanmugam; Estela Trebicka; Jos Boekhorst; Harro M Timmerman; Rian Roelofs; Erwin T Wiegerinck; Coby M Laarakkers; Dorine W Swinkels; Albert Bolhuis; Bobby J Cherayil; Harold Tjalsma
Journal:  Eur J Immunol       Date:  2015-06-23       Impact factor: 5.532

5.  Infliximab in pediatric inflammatory bowel disease rapidly decreases fecal calprotectin levels.

Authors:  Anssi Hämäläinen; Taina Sipponen; Kaija-Leena Kolho
Journal:  World J Gastroenterol       Date:  2011-12-21       Impact factor: 5.742

6.  Fecal calprotectin level in healthy children aged less than 4 years in South Korea.

Authors:  Joo Young Song; Yoo Mi Lee; You Jin Choi; Su Jin Jeong
Journal:  J Clin Lab Anal       Date:  2017-01-16       Impact factor: 2.352

7.  Geophagy is associated with environmental enteropathy and stunting in children in rural Bangladesh.

Authors:  Christine Marie George; Lauren Oldja; Shwapon Biswas; Jamie Perin; Gwenyth O Lee; Margaret Kosek; R Bradley Sack; Shahnawaz Ahmed; Rashidul Haque; Tahmina Parvin; Ishrat J Azmi; Sazzadul Islam Bhuyian; Kaisar A Talukder; Shahnaij Mohammad; Abu G Faruque
Journal:  Am J Trop Med Hyg       Date:  2015-04-27       Impact factor: 2.345

8.  Fecal calprotectin as a marker of the severity of mucosal inflammation in children with inflammatory bowel disease.

Authors:  Jernej Dolinšek; Petra Rižnik; Larisa Sabath; Dušanka Mičetić-Turk
Journal:  Wien Klin Wochenschr       Date:  2015-12-10       Impact factor: 1.704

9.  Inflammatory bowel disease activity assessed by fecal calprotectin and lactoferrin: correlation with laboratory parameters, clinical, endoscopic and histological indexes.

Authors:  Andrea Vieira; Chia Bin Fang; Ernani Geraldo Rolim; Wilmar Artur Klug; Flávio Steinwurz; Lucio Giovanni Battista Rossini; Paulo Azevedo Candelária
Journal:  BMC Res Notes       Date:  2009-10-29

10.  Fecal calprotectin excretion in preterm infants during the neonatal period.

Authors:  Carole Rougé; Marie-José Butel; Hugues Piloquet; Laurent Ferraris; Arnaud Legrand; Michel Vodovar; Marcel Voyer; Marie-France de la Cochetière; Dominique Darmaun; Jean-Christophe Rozé
Journal:  PLoS One       Date:  2010-06-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.